

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BCCA treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care.

PROTOCOL CODE: ULKCMLP

A BCCA "Compassionate Access Program" request form must be completed and approved prior to treatment

DOCTOR'S ORDERS Htcm Wtkg BS	6Am²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form	
DATE: To be given:	Cycle #:
 □ Delay treatment week(s) May proceed with doses as written if within 7 days of PONAtinib initiation, then within 10 days of dispensing the next cycle for first 6 months of therapy; thereafter, within 28 days of dispensing the next cycle. • ANC greater than or equal to 1.5 x 10⁹/L, Platelets greater than or equal to 75 x 10⁹/L. Dose modification for: □ Hematology □ Cardiac Risk □ Diarrhea □ Other Toxicity 	
CHEMOTHERAPY: PONAtinib ☐ 45 mg (standard dose) or ☐ 30mg or ☐ 15mg (select one) PO once daily Mitte: months (1-month supply for first 6 months of therapy; may dispense 3-month supply after 6 months) Refill x	Pharmacy Use Only Log Completed:
RETURN APPOINTMENT ORDERS	
Return in weeks for Doctor and cycle	
CBC & Diff, Platelets, serum lipase every 2 weeks for the first 3 months Months 1-3: ALT, Bilirubin monthly or as clinically indicated After 3 months: CBC & Diff, Platelets monthly ALT, Bilirubin monthly and as clinically indicated (in patients with transaminase elevations, perform hepatic enzyme tests more frequently) Electrolytes, magnesium, calcium, phosphorous, serum lipase every 3 months or as clinically indicated Peripheral blood analysis for quantitative RT-PCR (for BCR/ABL transcripts) every 3 months and mutational analysis As clinically indicated: Echocardiography ECG Other tests: Consults: See general orders sheet for additional requests.	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: